GS

924.4

+2.81%↑

RY

178.36

+1.7%↑

TD

105.31

+1.19%↑

BMO

151.94

+1.96%↑

CM

109.16

+1.55%↑

GS

924.4

+2.81%↑

RY

178.36

+1.7%↑

TD

105.31

+1.19%↑

BMO

151.94

+1.96%↑

CM

109.16

+1.55%↑

GS

924.4

+2.81%↑

RY

178.36

+1.7%↑

TD

105.31

+1.19%↑

BMO

151.94

+1.96%↑

CM

109.16

+1.55%↑

GS

924.4

+2.81%↑

RY

178.36

+1.7%↑

TD

105.31

+1.19%↑

BMO

151.94

+1.96%↑

CM

109.16

+1.55%↑

GS

924.4

+2.81%↑

RY

178.36

+1.7%↑

TD

105.31

+1.19%↑

BMO

151.94

+1.96%↑

CM

109.16

+1.55%↑

Search

MetLife Inc.

Slēgts

SektorsFinanšu

78.11 1.43

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

77.02

Max

78.59

Galvenie mērījumi

By Trading Economics

Ienākumi

-87M

809M

Pārdošana

6.9B

24B

P/E

Sektora vidējais

16

37.733

Dividenžu ienesīgums

3.04

Peļņas marža

3.397

Darbinieki

46,000

EBITDA

-101M

1.4B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+18.51% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.04%

4.63%

Nākamie ieņēmumi

2026. g. 6. maijs

Nākamais dividenžu datums

2026. g. 9. jūn.

Nākamais Ex dividenžu datums

2026. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-3.4B

50B

Iepriekšējā atvēršanas cena

76.68

Iepriekšējā slēgšanas cena

78.11

Ziņu noskaņojums

By Acuity

28%

72%

78 / 440 Rangs Finance

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

MetLife Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. apr. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026. g. 17. apr. 18:15 UTC

Galvenie ziņu notikumi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026. g. 17. apr. 22:58 UTC

Peļņas

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026. g. 17. apr. 21:32 UTC

Tirgus saruna

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Moody's Downgrades Belgium to A1 -- Market Talk

2026. g. 17. apr. 20:52 UTC

Peļņas

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026. g. 17. apr. 20:50 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. apr. 20:29 UTC

Peļņas

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026. g. 17. apr. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026. g. 17. apr. 19:34 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2026. g. 17. apr. 19:34 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026. g. 17. apr. 19:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026. g. 17. apr. 19:26 UTC

Tirgus saruna

U.S. Natural Gas Futures Edge Up -- Market Talk

2026. g. 17. apr. 19:21 UTC

Tirgus saruna

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026. g. 17. apr. 19:15 UTC

Tirgus saruna

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026. g. 17. apr. 19:07 UTC

Tirgus saruna

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026. g. 17. apr. 18:57 UTC

Galvenie ziņu notikumi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB 2026 Rev Guidance Unchanged

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026. g. 17. apr. 18:14 UTC

Tirgus saruna
Galvenie ziņu notikumi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026. g. 17. apr. 17:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026. g. 17. apr. 17:26 UTC

Tirgus saruna
Peļņas

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Salīdzinājums

Cenas izmaiņa

MetLife Inc. Prognoze

Cenas mērķis

By TipRanks

18.51% augšup

Prognoze 12 mēnešiem

Vidējais 91.36 USD  18.51%

Augstākais 102 USD

Zemākais 81 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MetLife Inc. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

9

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

75.86 / 77.81Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

78 / 440 Rangs Finanšu

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par MetLife Inc.

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was incorporated in 1999 and is based in New York, New York.
help-icon Live chat